Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Bristol-Myers Squibb Co's Enterprise Value is CHF131,583 Mil.
Bristol-Myers Squibb Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was CHF10,652 Mil. Therefore, Bristol-Myers Squibb Co's EV-to-OCF for today is 12.35.
The historical rank and industry rank for Bristol-Myers Squibb Co's EV-to-OCF or its related term are showing as below:
XSWX:BMY'
s EV-to-OCF Range Over the Past 10 Years
Min: 7.43 Med: 12.35 Max: 78.97
Current: 12.14
During the past 13 years, the highest EV-to-OCF of Bristol-Myers Squibb Co was 78.97. The lowest was 7.43. And the median was 12.35.
XSWX:BMY's EV-to-OCF is ranked worse than 53.82% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 10.41
vs XSWX:BMY: 12.14
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bristol-Myers Squibb Co (XSWX:BMY) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bristol-Myers Squibb Co's PE Ratio (TTM) for today is calculated as:
Bristol-Myers Squibb Co's share price for today is CHF50.31.
Bristol-Myers Squibb Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF2.833.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bristol-Myers Squibb Co EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Bristol-Myers Squibb Co's EV-to-OCF falls into.
Bristol-Myers Squibb Co's current Enterprise Value is CHF131,583 Mil.
Bristol-Myers Squibb Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF10,652 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bristol-Myers Squibb Co (XSWX:BMY) has a EV-to-OCF of 12.35 as of Jul. 24, 2026. This is near median its historical median of 12.35. Over the past decade, Bristol-Myers Squibb Co's EV-to-OCF has ranged from 7.43 to 78.97. According to the industry distribution chart, Bristol-Myers Squibb Co ranks #542 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 53.8%.
Is Bristol-Myers Squibb Co's EV-to-OCF too high?
Bristol-Myers Squibb Co's current EV-to-OCF of 12.35 is near median its 10-year median of 12.35. Over the past 10 years, this metric has ranged from a low of 7.43 to a high of 78.97. The Drug Manufacturers industry median EV-to-OCF is 10.41. Bristol-Myers Squibb Co's value of 12.35 is 18.6% above this industry median. Based on the distribution chart, Bristol-Myers Squibb Co ranks #542 out of 1007 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Bristol-Myers Squibb Co has a GF Score™ of 78/100, reflecting its overall financial health beyond just this single metric.
How does Bristol-Myers Squibb Co's EV-to-OCF compare to PFE and GILD?
According to the Drug Manufacturers industry distribution chart, Bristol-Myers Squibb Co ranks #542 out of 1007 companies for EV-to-OCF. This places Bristol-Myers Squibb Co in the lower half of its industry. The industry median EV-to-OCF is 10.41. Bristol-Myers Squibb Co's value of 12.35 is 18.6% above this benchmark. Historically, Bristol-Myers Squibb Co's own EV-to-OCF has ranged from 7.43 to 78.97 over the past decade. While the company's 10-year median is 12.35 vs. the industry median of 10.41, Bristol-Myers Squibb Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.41, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bristol-Myers Squibb Co's current EV-to-OCF of 12.35 is 18.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bristol-Myers Squibb Co's current EV-to-OCF is 12.35, which is near median its own 10-year median of 12.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bristol-Myers Squibb Co stock overvalued right now?
Bristol-Myers Squibb Co (XSWX:BMY) has a current EV-to-OCF of 12.35. The stock's GF Value™ is CHF45.07, compared to a current price of CHF50.31 — trading 11.6% above its estimated fair value. The current EV-to-OCF is 12.35, which is near median its 10-year median of 12.35 and 18.6% above the Drug Manufacturers industry median of 10.41. Bristol-Myers Squibb Co's overall GF Score™ is 78/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Bristol-Myers Squibb Co (XSWX:BMY), the current EV-to-OCF is 12.35 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bristol-Myers Squibb Co (XSWX:BMY) Overvalued in 2026?
Based on GuruFocus' analysis, Bristol-Myers Squibb Co stock appears to be overvalued.
The current stock price of CHF50.31 is trading 11.6% above its estimated GF Value™ of CHF45.07.
Key valuation signals for XSWX:BMY:
EV-to-OCF: 12.35 (near median its 10-year median of 12.35)
GF Value™: CHF45.07 vs. price of CHF50.31 (11.6% above fair value)
Industry Position: 18.6% above the Drug Manufacturers median (#542 of 1007)
No single metric tells the full story. See the XSWX:BMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
78GF Score
Get the complete analysis for XSWX:BMY
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BMY has been successfully added to your 
